Journals / Harran Üniversitesi Tıp Fakültesi Dergisi / 2020 / Cilt: 17 - Sayı: 3

Does Diltiazem Provide Benefits on Allograft Functions in Kidney Transplant Recipients?

Diltiazem Böbrek Alıcılarında Greft Fonksiyonlarını İyileştirir mi?

Pages
425–430
Publication Date
2020-12-25
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Key Words: Allograft function, Diltiazem, Kidney transplantation

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Acute and chronic calcineurin inhibitors (CNI) nephrotoxicity is a common concern in kidney transplant (KT) recipients.
📊
Key Findings & Data:In this study, we investigated the impact of diltiazem on 1 –year allograft survival and function.Materials and Methods: This single-center retrospective study included 312 kidney transplant recipients and donors.
💡
Conclusion & Impact:Key Words: Allograft function, Diltiazem, Kidney transplantation
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Böbrek Nakli · Diltiazem · Greft sağkalımı

Abstract

Background: Acute and chronic calcineurin inhibitors (CNI) nephrotoxicity is a common concern in kidney transplant (KT) recipients. It is unclear whether diltiazem use can reduce CNI induced acute and chronic nephrotoxicity in (KT) recipients. In this study, we investigated the impact of diltiazem on 1 –year allograft survival and function.Materials and Methods: This single-center retrospective study included 312 kidney transplant recipients and donors. Diltiazem receiving and diltiazem-free recipients were compared for 1-year allograft survival and functions. Available allograft biopsies were investigated for the evidence pieces of CNI induced nephrotoxicity. Factors may have a potential impact on allograft functions were evaluated (cytomegalovirus and polyoma BK viremia positivity, acute rejection episodes, donors and recipients ages and body mass indexes). A statistical package program was used for data analysis. P<0.05 was assigned significant.Results: Seventy-three recipients in diltiazem arm and 239 in diltiazem-free arm were compared. In diltiazem and diltiazem-free arms, 1- year mortality, allograft survival rates and CNI induced nephrotoxicity incidences were 4.1% vs 3.8% (P=0.89), and 13.7% vs 7.1% (P=0.08), 18.8% vs 10.5% (P=0.27), respectively. However, 12-month estimated glomerular filtration rate was worse in diltiazem arm (62.75 ml/dk/1.73m2) compared to diltiazem-free group (73.19 ml/dk/1.73m2) (P=0.03). CNI toxicity had a weak impact on low eGFR in regression analysis (P=0.055 and 95% confidence interval).Conclusions: Despite diltiazem use allows to CNI dose reduction, it might have undesirable impacts on long-term allograft functions, which is the main target of the allograft care. Key Words: Allograft function, Diltiazem, Kidney transplantation

Özet

Amaç: Akut ve kronik kalsinörin inhibitörü (KNİ) toksisitesi böbrek naklinde önemli bir sorundur. Diltiazem kullanımının KNİ toksisitesini azaltıp azaltmadığı net değildir. Bu çalışmada KNİ kullanımının 1 yıllık greft sağkalımı ve fonksiyonu üzerine etkilerini araştırdık.Materyal ve Metod: Bu tek merkezli retrospektif çalışmada 312 böbrek alıcısı ve vericisi incelendi. Alıcılar diltiazem kullanan ve kullanmayan guruplar olarak ikiye ayrıldı. 1 yıllık alıcı ve greft sağkalımları araştırıldı. Greft biyopsilerinde KNİ toksisitesi ile 1 yıllık greft sağ kalımı arasındaki ilişki incelendi. Sitomegalovirüs ve polyoma BK virüs viremisi varlığı, akut rejeksiyon atakları, alıcı ve vericinin yaşları ve vücut kitle indekslerinin 1 yıllık greft sağ kalımı üzerine etkileri araştırıldı. Veriler bir istatistik paket programda değerlendirildi, P<0,05 anlamlı kabul edildi. Bulgular: Alıcıların 73’ü diltiazem kullandı, 239’u diltiazem kullanmadı. 1 yıllık mortalite, greft sağ kalımı, Kalsinörin inhibitörü ilişkili nefrotoksisite diltiazem kolunda ve diltiazem kullanmayan gurupta sırasıyla; %4,1 e karşı %3,8 (P=0,89), %13,7’ye karşı %7,1 (P=0.08) ve %18,8’e karşı %10,5 (P=0,27) idi. 12 ay sonunda tahmini glomerüler filtrasyon hızı diltiazem kolunda daha kötü idi; 62,75 ml/dk/1.73m2’ye karşı 73,19 ml/dk/1,73m2 (P=0.03). Kalsinörin inhibitörü toksisitesinin kötü greft fonksiyonları üzerine %95 güven aralığında zayıf bir etkisi görüldü (P=0.055).Sonuç: Diltiazem KNİ doz azaltımına imkân sağlasa da esasen istenen uzun dönem greft fonksiyonları üzerine olumsuz etkilere sahip olabilir.

🔖

Cite This Article

DEMİR, M. E., MERHAMETSİZ, Ö., UYAR, M., SEVMİS, M., AKTAS, S., SEVMİŞ, Ş. (2020). Does Diltiazem Provide Benefits on Allograft Functions in Kidney Transplant Recipients?. Harran Üniversitesi Tıp Fakültesi Dergisi, Cilt: 17 - Sayı: 3, 425–430. https://ajindex.com/articles/88100

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Karpe KM, Talaulikar GS, Walters GD. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients. Cochrane Database Syst Rev. 2017;21;7(7):CD006750
  2. Bentata Y. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity. Artif Organs. 2020;44(2):140-52
  3. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349(24):2326-33
  4. Farouk SS, Rein JL. The Many Faces of Calcineurin Inhibitor Toxicity-What the FK? Adv Chronic Kidney Dis. 2020;27(1):56-66
  5. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010;20;(1):CD007893
  6. Tory R, Sachs-Barrable K, Hill JS, Wasan KM. Cyclosporine A and Rapamycin induce in vitro cholesteryl ester transfer protein activity, and suppress lipoprotein lipase activity in human plasma. Int J Pharm. 2008;358(1-2):219-23
  7. Awan AA, Niu J, Pan JS, Erickson KF, Mandayam S, Winkelmayer WC, Navaneethan SD, Ramanathan V. Trends in the Causes of Death among Kidney Transplant Recipients in the United States (1996-2014). Am J Nephrol. 2018;48(6):472-81
  8. Weiner DA, Cutler SS, Klein MD. Efficacy and safety of sustained-release diltiazem in stable angina pectoris. D'Amico D, Tepper SJ. Prophylaxis of migraine: general principles and patient acceptance. Neuropsychiatr Dis Treat. 2008;4(6):1155-67
  9. Islam S, Masiakos P, Schnitzer JJ, Doody DP, Ryan DP. Diltiazem reduces pulmonary arterial pressures in recurrent pulmonary hypertension associated with pulmonary hypoplasia. J Pediatr Surg. 1999;34(5):712-4
  10. Choong CL, Wong HS, Lee FY, Lee CK, Kho JV, Lai YX, Vikneswaran T. Dose-Response Relationship Between Diltiazem and Tacrolimus and Its Safety in Renal Transplant Recipients. Transplant Proc. 2018;50(8):2515-20
  11. Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol Ther. 2006;109(1-2):137-61
  12. Steuber TD, Lee J, Holloway A, Andrus MR. Nondihydropyridine Calcium Channel Blockers for the Treatment of Proteinuria: A Review of the Literature. Ann Pharmacother. 2019;53(10):1050-9
  13. Xue W, Song Y, Tian P, Ding X, Pan X, Yan H, Hou J, Feng X, Xiang H, Tian X. The effects of diltiazem in renal transplantation patients treated with cyclosporine A. J Biomed Res. 2010;24(4):317-23
  14. Azmandian J, Sohrevardi SM, Fazeli F, Sarrafzadeh F, Etminan A, Savari O, et al. Dil